EUVIMEDObjevte EUVIMED
Crossref

Effectiveness of Catheter Ablation for Patients With Atrial Fibrillation and Heart Failure

Zhou Le iD, Jue Wang, Yize Zhao iD, Song Zuo, Liu He, Xiangyi Kong, Xin Li, Jiang Chao iD, Wenli Dai, Lizhu Guo, Liu Xiaoxia, Guo Xueyuan and 12 more

Pacing and Clinical Electrophysiology · 2025

DOI: 10.1111/pace.70073 ↗

At a glance

Journal article in Pacing and Clinical Electrophysiology, 2025. Written by Zhou Le and 23 co-authors. Institution: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing…. Major MEDLINE topics: Atrial Fibrillation, Catheter Ablation, Heart Failure. 24 references. Funded by: the National Key Research and Development Program, from Science and Technology Program of Guangdong Province, the Chinese Atrial Fibrillation Registry.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Atrial fibrillation (AF) is frequently complicated by heart failure (HF), leading to increased morbidity and mortality. Catheter ablation (CA) has been shown in randomized controlled trials (RCTs) to improve outcomes in selected patients with AF and heart failure with reduced ejection fraction (HFrEF). However, the efficacy of CA compared with antiarrhythmic drug (AAD) therapy in patients with heart failure with preserved ejection fraction (HFpEF) has not been conclusively established. Consequently, real‐world evidence is needed to further clarify the potential benefits of CA across the broader spectrum of HF populations.

Objectives

Our research will investigate the impact of CA on the clinical prognosis of patients with AF and HF, compared to a pharmacological treatment approach.

Methods

Patients with AF and HF were prospectively enrolled from August 2011 to December 2020 in the China‐AF Registry. The efficacy of CA versus pharmacological treatment was evaluated in propensity score matched (PSM) cohorts using Cox proportional hazards analysis. The primary endpoint was all‐cause mortality, with secondary endpoints including thromboembolism and cardiovascular death.

Results

From a cohort of 3072 AF and HF patients, 2529 were analyzed (678 underwent CA and 1851 received pharmacological treatment). Propensity score matching resulted in 604 patients per group, well‐balanced (mean age 62.6 ± 10.5 years, 38.3% female), with 53.3% having persistent AF. Ablation patients underwent an average of 1.16 ± 0.41 procedures. Over a mean 4.16‐year follow‐up, CA group saw significantly fewer deaths (4.8% vs. 14.1%; adjusted HR 0.54, 95% CI 0.32–0.91; p < 0.001) compared to the pharmacological group after adjusting potential confounders. CA was also associated with a reduced risk of cardiovascular death (adjusted HR 0.35, 95% CI 0.17–0.74; p = 0.005) and thromboembolism (adjusted HR 0.48, 95% CI 0.26–0.88; p = 0.020), after adjusting medication use.

Conclusions

In patients with AF and HF, CA was associated with improved clinical outcomes compared to pharmacological treatment in this real‐world cohort. Nevertheless, residual confounding cannot be excluded, and the findings should be interpreted with caution pending confirmation from prospective randomized studies. Trial Registration www.chictr.org.cn . Identifier: ChiCTR‐OCH‐13003729.

Subjects

MeSH terms (MEDLINE)

Atrial FibrillationCatheter AblationHeart FailureHumansMaleFemaleMiddle AgedAnti-Arrhythmia AgentsTreatment OutcomeProspective StudiesRegistriesAgedChina

Author keywords

atrial fibrillationcatheter ablationheart failure

Substances

Anti-Arrhythmia Agents

Authors and institutions

  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China.

ORCID profiles: Zhou Le, Yize Zhao, Jiang Chao, Nian Liu, Deyong Long, Changsheng Ma

Funding

  • the National Key Research and Development Program
  • from Science and Technology Program of Guangdong Province
  • the Chinese Atrial Fibrillation Registry
  • from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI), and Bayer

Cite

APA

Le, Z., Wang, J., Zhao, Y., Zuo, S., He, L., Kong, X., Li, X., Chao, J., Dai, W., Guo, L., Xiaoxia, L., Xueyuan, G., Li, C., Zhao, X., Wang, W., Li, S., Jiang, C., Liu, N., Tang, R., …, & Ma, C. (2025). Effectiveness of Catheter Ablation for Patients With Atrial Fibrillation and Heart Failure. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.70073

Vancouver

Le Z, Wang J, Zhao Y, Zuo S, He L, Kong X, et al. Effectiveness of Catheter Ablation for Patients With Atrial Fibrillation and Heart Failure. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.70073

BibTeX
@article{Le2025,
  author = {Le, Zhou and Wang, Jue and Zhao, Yize and Zuo, Song and He, Liu and Kong, Xiangyi and Li, Xin and Chao, Jiang and Dai, Wenli and Guo, Lizhu and Xiaoxia, Liu and Xueyuan, Guo and Li, Changyi and Zhao, Xin and Wang, Wei and Li, Songnan and Jiang, Chenxi and Liu, Nian and Tang, Ribo and Sang, Caihua and Long, Deyong and Du, Xin and Dong, Jianzeng and Ma, Changsheng},
  title = {Effectiveness of Catheter Ablation for Patients With Atrial Fibrillation and Heart Failure},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2025},
  doi = {10.1111/pace.70073}
}
Start for free →